The boards of directors for both companies unanimously approved the transaction.
Officials expect to close the deal by the end of February.
“[The transaction has allowed] us to not only accelerate our mission to discover, develop and deliver precision therapies to patients with rare cancers, but also deliver meaningful value to our shareholders through a substantial cash premium,” said President and CEO of ARIAD Pharmaceuticals Paris Panayiotopoulos. “This exciting transaction is a testament to the hard work and dedication of ARIAD’s talented team of employees. We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition.”
More articles on supply chain:
Sen. Amy Klobuchar calls on Teleflex to fix defective naloxone spray
Novartis partners with Ionis Pharma for 2 heart drugs in $1B deal: 4 things to know
4 latest FDA approvals
